Study Evaluating Prevenar in the Prevention of Invasive Pneumococcal Disease (IPD) in the Paediatric Population in Spain.

The aim of this study is to evaluate the postlicensure effectiveness of Prevnar in the prevention of IPD in the Spanish paediatric population (children younger than 5 years)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Invasive Pneumococcal Disease

Age range

Up to 5 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Pfizer Investigational Site

Bilbao, 48903, Spain

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

All children from 0 up to 5 years attending to the hospital's emergency department will be evaluated for IPD.
Diagnosis of IPD will be based on positive pneumococcal isolation in any sterile location, such us blood or spinal fluid.

Treatment and study plan

Pneumococcal 7-valent conjugate vaccine Prevnar

Drug

Other names: PREVNAR

Sponsors and collaborators

Lead sponsor

Pfizer

Industry

Registry information

Official study title

Effectiveness of Prevnar in the Prevention on IPD in the Paediatric Population in Spain

Important dates

Study start: 2003
Primary completion: 2005
Study completion: 2005
First posted: Sep 27, 2005
Registry last updated: Nov 29, 2012

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed